 Cathy Bradley
Concepts (479)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 63 | 2024 | 2082 | 10.720 |
Why?
| | Employment | 37 | 2024 | 137 | 9.750 |
Why?
| | Medicaid | 37 | 2023 | 404 | 8.530 |
Why?
| | Breast Neoplasms | 47 | 2023 | 1842 | 6.150 |
Why?
| | Cancer Survivors | 14 | 2023 | 208 | 4.710 |
Why?
| | Insurance Coverage | 20 | 2023 | 199 | 4.320 |
Why?
| | Insurance, Health | 19 | 2023 | 243 | 4.020 |
Why?
| | Medicare | 34 | 2023 | 661 | 3.720 |
Why?
| | SEER Program | 21 | 2022 | 193 | 3.210 |
Why?
| | Poverty | 13 | 2022 | 437 | 3.170 |
Why?
| | Healthcare Disparities | 14 | 2020 | 479 | 2.850 |
Why?
| | Cost of Illness | 13 | 2022 | 255 | 2.790 |
Why?
| | Colorectal Neoplasms | 15 | 2022 | 592 | 2.730 |
Why?
| | Medically Uninsured | 12 | 2020 | 122 | 2.660 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2020 | 208 | 2.540 |
Why?
| | United States | 89 | 2023 | 12137 | 2.490 |
Why?
| | Early Detection of Cancer | 9 | 2022 | 305 | 2.380 |
Why?
| | Survivors | 16 | 2022 | 414 | 2.210 |
Why?
| | Registries | 31 | 2023 | 1762 | 2.160 |
Why?
| | Health Services Accessibility | 16 | 2023 | 756 | 2.110 |
Why?
| | Health Benefit Plans, Employee | 5 | 2022 | 20 | 1.970 |
Why?
| | Humans | 187 | 2024 | 113531 | 1.880 |
Why?
| | Caregivers | 6 | 2023 | 713 | 1.810 |
Why?
| | Health Care Costs | 13 | 2022 | 381 | 1.770 |
Why?
| | Survivorship | 4 | 2022 | 41 | 1.740 |
Why?
| | Antineoplastic Agents | 8 | 2020 | 1872 | 1.580 |
Why?
| | Health Care Reform | 4 | 2021 | 92 | 1.570 |
Why?
| | Medical Oncology | 5 | 2023 | 229 | 1.500 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 5 | 2020 | 953 | 1.480 |
Why?
| | Drug Costs | 3 | 2023 | 91 | 1.480 |
Why?
| | Aged | 70 | 2023 | 18944 | 1.410 |
Why?
| | Colonic Neoplasms | 5 | 2016 | 210 | 1.400 |
Why?
| | Mental Health | 4 | 2023 | 559 | 1.390 |
Why?
| | Female | 118 | 2023 | 59115 | 1.390 |
Why?
| | Socioeconomic Factors | 20 | 2022 | 1080 | 1.310 |
Why?
| | Research | 6 | 2022 | 387 | 1.290 |
Why?
| | Policy | 4 | 2024 | 137 | 1.270 |
Why?
| | Lung Neoplasms | 10 | 2020 | 2148 | 1.270 |
Why?
| | Middle Aged | 69 | 2023 | 26552 | 1.260 |
Why?
| | Michigan | 24 | 2015 | 96 | 1.260 |
Why?
| | Prostatic Neoplasms | 10 | 2022 | 911 | 1.210 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1159 | 1.190 |
Why?
| | Prescription Drugs | 2 | 2023 | 116 | 1.180 |
Why?
| | Health Status Disparities | 2 | 2023 | 200 | 1.150 |
Why?
| | Health Status | 10 | 2013 | 716 | 1.140 |
Why?
| | Income | 7 | 2023 | 166 | 1.140 |
Why?
| | Medical Record Linkage | 2 | 2021 | 53 | 1.070 |
Why?
| | Aged, 80 and over | 35 | 2020 | 6296 | 1.060 |
Why?
| | Male | 86 | 2022 | 55112 | 1.060 |
Why?
| | Papanicolaou Test | 2 | 2017 | 38 | 1.040 |
Why?
| | Primary Health Care | 6 | 2023 | 1502 | 1.030 |
Why?
| | Motivation | 2 | 2020 | 486 | 0.990 |
Why?
| | Adult | 60 | 2023 | 30245 | 0.980 |
Why?
| | Patient Acceptance of Health Care | 4 | 2018 | 679 | 0.960 |
Why?
| | Efficiency | 6 | 2016 | 84 | 0.960 |
Why?
| | Safety-net Providers | 3 | 2017 | 96 | 0.940 |
Why?
| | Mass Screening | 10 | 2022 | 978 | 0.890 |
Why?
| | Comorbidity | 12 | 2019 | 1443 | 0.880 |
Why?
| | Eligibility Determination | 5 | 2018 | 59 | 0.880 |
Why?
| | Colonoscopy | 4 | 2019 | 197 | 0.850 |
Why?
| | Health Expenditures | 8 | 2023 | 172 | 0.830 |
Why?
| | Quality of Life | 6 | 2023 | 2335 | 0.810 |
Why?
| | Return to Work | 4 | 2022 | 19 | 0.810 |
Why?
| | Absenteeism | 4 | 2013 | 40 | 0.800 |
Why?
| | Virginia | 7 | 2018 | 50 | 0.770 |
Why?
| | Workplace | 4 | 2021 | 221 | 0.760 |
Why?
| | Health Equity | 1 | 2022 | 53 | 0.750 |
Why?
| | Medication Adherence | 2 | 2023 | 530 | 0.720 |
Why?
| | Cancer Care Facilities | 3 | 2023 | 29 | 0.710 |
Why?
| | Perioperative Care | 1 | 2021 | 127 | 0.690 |
Why?
| | Cost Sharing | 1 | 2020 | 14 | 0.680 |
Why?
| | Information Dissemination | 1 | 2022 | 185 | 0.670 |
Why?
| | Models, Economic | 2 | 2011 | 48 | 0.670 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 332 | 0.650 |
Why?
| | Mammography | 3 | 2014 | 101 | 0.640 |
Why?
| | Preventive Health Services | 5 | 2023 | 134 | 0.630 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 24 | 0.620 |
Why?
| | Health Facilities | 1 | 2019 | 71 | 0.620 |
Why?
| | Spouses | 3 | 2017 | 86 | 0.620 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 278 | 0.600 |
Why?
| | Young Adult | 22 | 2022 | 10400 | 0.600 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 285 | 0.590 |
Why?
| | Survival Analysis | 10 | 2019 | 1203 | 0.590 |
Why?
| | Retirement | 4 | 2022 | 25 | 0.570 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 35 | 0.560 |
Why?
| | Job Satisfaction | 3 | 2013 | 168 | 0.540 |
Why?
| | Length of Stay | 6 | 2012 | 963 | 0.540 |
Why?
| | Healthy People Programs | 1 | 2016 | 8 | 0.530 |
Why?
| | Logistic Models | 13 | 2023 | 1832 | 0.530 |
Why?
| | Bevacizumab | 1 | 2017 | 113 | 0.530 |
Why?
| | Occupational Health Services | 2 | 2016 | 31 | 0.530 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 157 | 0.530 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 512 | 0.520 |
Why?
| | Chronic Pain | 1 | 2019 | 207 | 0.520 |
Why?
| | Outpatients | 1 | 2019 | 324 | 0.520 |
Why?
| | Job Description | 2 | 2013 | 10 | 0.510 |
Why?
| | Massachusetts | 4 | 2021 | 134 | 0.510 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 121 | 0.480 |
Why?
| | Nursing Homes | 4 | 2013 | 138 | 0.480 |
Why?
| | Fee-for-Service Plans | 4 | 2023 | 83 | 0.470 |
Why?
| | State Government | 3 | 2014 | 41 | 0.470 |
Why?
| | Vaginal Smears | 1 | 2014 | 48 | 0.460 |
Why?
| | Longitudinal Studies | 10 | 2022 | 2361 | 0.460 |
Why?
| | Mouth Neoplasms | 3 | 2019 | 70 | 0.450 |
Why?
| | Health Personnel | 3 | 2022 | 569 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1356 | 0.440 |
Why?
| | Health Services Research | 4 | 2010 | 373 | 0.440 |
Why?
| | Emergency Treatment | 1 | 2015 | 113 | 0.440 |
Why?
| | General Practice | 1 | 2014 | 27 | 0.440 |
Why?
| | Delivery of Health Care | 5 | 2024 | 828 | 0.430 |
Why?
| | Sick Leave | 2 | 2019 | 13 | 0.430 |
Why?
| | Databases, Factual | 7 | 2021 | 1127 | 0.430 |
Why?
| | Behavioral Risk Factor Surveillance System | 4 | 2017 | 44 | 0.410 |
Why?
| | Sickness Impact Profile | 1 | 2013 | 50 | 0.410 |
Why?
| | Cost-Benefit Analysis | 8 | 2017 | 542 | 0.410 |
Why?
| | Survival Rate | 7 | 2020 | 1634 | 0.400 |
Why?
| | Insurance Claim Review | 2 | 2010 | 68 | 0.400 |
Why?
| | Age Factors | 11 | 2022 | 2875 | 0.400 |
Why?
| | Marital Status | 3 | 2007 | 41 | 0.400 |
Why?
| | Homes for the Aged | 2 | 2013 | 19 | 0.400 |
Why?
| | Value of Life | 2 | 2008 | 18 | 0.390 |
Why?
| | Quality Improvement | 2 | 2018 | 951 | 0.390 |
Why?
| | Work | 3 | 2010 | 17 | 0.390 |
Why?
| | Cross-Sectional Studies | 11 | 2023 | 4400 | 0.390 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 519 | 0.380 |
Why?
| | Risk Factors | 13 | 2021 | 8606 | 0.380 |
Why?
| | Periodicals as Topic | 2 | 2023 | 180 | 0.370 |
Why?
| | Health Services | 1 | 2012 | 103 | 0.360 |
Why?
| | Social Class | 4 | 2022 | 203 | 0.360 |
Why?
| | Surgical Procedures, Operative | 2 | 2012 | 208 | 0.360 |
Why?
| | Biomedical Research | 2 | 2020 | 581 | 0.350 |
Why?
| | Physician Self-Referral | 1 | 2010 | 1 | 0.350 |
Why?
| | Intestinal Perforation | 3 | 2016 | 39 | 0.340 |
Why?
| | Physicians | 1 | 2018 | 765 | 0.340 |
Why?
| | Waiting Lists | 1 | 2011 | 204 | 0.340 |
Why?
| | Recovery of Function | 1 | 2013 | 567 | 0.330 |
Why?
| | Financing, Personal | 2 | 2019 | 24 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 575 | 0.330 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2016 | 100 | 0.330 |
Why?
| | Astrocytoma | 1 | 2010 | 106 | 0.330 |
Why?
| | Data Collection | 3 | 2014 | 616 | 0.330 |
Why?
| | Radiation Oncology | 1 | 2010 | 74 | 0.320 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 195 | 0.320 |
Why?
| | Surveys and Questionnaires | 11 | 2018 | 4593 | 0.320 |
Why?
| | Administration, Oral | 2 | 2023 | 719 | 0.320 |
Why?
| | Propensity Score | 1 | 2010 | 225 | 0.310 |
Why?
| | Life Expectancy | 1 | 2008 | 45 | 0.310 |
Why?
| | HIV Infections | 2 | 2022 | 2440 | 0.310 |
Why?
| | Dentists | 1 | 2008 | 18 | 0.310 |
Why?
| | Persuasive Communication | 1 | 2008 | 12 | 0.310 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2018 | 39 | 0.300 |
Why?
| | Dental Care | 1 | 2008 | 29 | 0.300 |
Why?
| | Multivariate Analysis | 9 | 2019 | 1421 | 0.300 |
Why?
| | Odds Ratio | 9 | 2014 | 953 | 0.290 |
Why?
| | Communication | 2 | 2019 | 734 | 0.290 |
Why?
| | Pneumonectomy | 1 | 2008 | 118 | 0.280 |
Why?
| | Depression | 4 | 2021 | 1131 | 0.280 |
Why?
| | Patient Education as Topic | 1 | 2011 | 665 | 0.280 |
Why?
| | Models, Econometric | 5 | 2017 | 34 | 0.280 |
Why?
| | Time Factors | 11 | 2013 | 6032 | 0.270 |
Why?
| | Likelihood Functions | 5 | 2021 | 123 | 0.260 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 366 | 0.260 |
Why?
| | Confidence Intervals | 4 | 2013 | 302 | 0.260 |
Why?
| | Quality-Adjusted Life Years | 4 | 2017 | 103 | 0.250 |
Why?
| | Myocardial Infarction | 3 | 2023 | 932 | 0.250 |
Why?
| | Anxiety | 3 | 2021 | 837 | 0.250 |
Why?
| | Cohort Studies | 7 | 2023 | 4880 | 0.250 |
Why?
| | Online Systems | 1 | 2005 | 23 | 0.250 |
Why?
| | Cross Infection | 2 | 2017 | 195 | 0.250 |
Why?
| | Referral and Consultation | 1 | 2010 | 632 | 0.240 |
Why?
| | Colonic Diseases | 2 | 2016 | 26 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2014 | 2088 | 0.240 |
Why?
| | Disability Evaluation | 1 | 2007 | 271 | 0.240 |
Why?
| | Cost Savings | 2 | 2018 | 74 | 0.240 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2011 | 533 | 0.240 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 192 | 0.230 |
Why?
| | Health Services Needs and Demand | 3 | 2017 | 241 | 0.230 |
Why?
| | Needs Assessment | 2 | 2024 | 314 | 0.230 |
Why?
| | Models, Statistical | 4 | 2017 | 593 | 0.230 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 423 | 0.230 |
Why?
| | Substance-Related Disorders | 3 | 1997 | 931 | 0.230 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 459 | 0.220 |
Why?
| | Hospitals, Public | 1 | 2023 | 22 | 0.210 |
Why?
| | Colorado | 2 | 2023 | 4061 | 0.210 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 338 | 0.210 |
Why?
| | Forecasting | 5 | 2016 | 329 | 0.210 |
Why?
| | Intensive Care Units | 2 | 2017 | 620 | 0.210 |
Why?
| | Risk Assessment | 6 | 2022 | 2953 | 0.210 |
Why?
| | Carcinoma | 2 | 2017 | 198 | 0.200 |
Why?
| | Economics, Medical | 1 | 2022 | 4 | 0.200 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 770 | 0.200 |
Why?
| | Age Distribution | 4 | 2020 | 341 | 0.200 |
Why?
| | Incidence | 5 | 2022 | 2310 | 0.200 |
Why?
| | Brain Neoplasms | 1 | 2010 | 964 | 0.200 |
Why?
| | Hormones | 1 | 2023 | 132 | 0.200 |
Why?
| | Proportional Hazards Models | 5 | 2019 | 1076 | 0.200 |
Why?
| | Health Behavior | 2 | 2019 | 701 | 0.200 |
Why?
| | Colonic Polyps | 2 | 2014 | 67 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 848 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2019 | 9006 | 0.200 |
Why?
| | Bisexuality | 1 | 2022 | 17 | 0.200 |
Why?
| | Food Supply | 1 | 2022 | 63 | 0.200 |
Why?
| | Smoking | 2 | 2019 | 1380 | 0.200 |
Why?
| | Hospital Charges | 3 | 2003 | 39 | 0.190 |
Why?
| | Decision Making | 2 | 2005 | 761 | 0.190 |
Why?
| | Hospitalization | 5 | 2016 | 1765 | 0.190 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 662 | 0.180 |
Why?
| | Retrospective Studies | 12 | 2021 | 12504 | 0.180 |
Why?
| | Internet | 1 | 2005 | 590 | 0.180 |
Why?
| | Sex Factors | 5 | 2022 | 1705 | 0.180 |
Why?
| | Homosexuality, Male | 1 | 2022 | 169 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2023 | 737 | 0.170 |
Why?
| | Population Surveillance | 2 | 2022 | 385 | 0.170 |
Why?
| | Stress, Psychological | 2 | 2021 | 940 | 0.170 |
Why?
| | Kentucky | 1 | 2020 | 35 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 71 | 0.170 |
Why?
| | California | 2 | 2018 | 351 | 0.170 |
Why?
| | Benzodiazepines | 1 | 2021 | 114 | 0.170 |
Why?
| | Probability | 4 | 2023 | 285 | 0.170 |
Why?
| | Adolescent | 12 | 2020 | 17724 | 0.170 |
Why?
| | Sample Size | 1 | 2000 | 107 | 0.170 |
Why?
| | Carrier State | 2 | 2017 | 54 | 0.170 |
Why?
| | Regression Analysis | 5 | 2021 | 932 | 0.170 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.170 |
Why?
| | Ownership | 2 | 2010 | 79 | 0.160 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 896 | 0.160 |
Why?
| | Patient Selection | 3 | 2010 | 625 | 0.160 |
Why?
| | Infection Control | 2 | 2017 | 130 | 0.160 |
Why?
| | Language Development Disorders | 1 | 2019 | 38 | 0.160 |
Why?
| | Activities of Daily Living | 2 | 2010 | 348 | 0.160 |
Why?
| | Infant, Newborn | 4 | 2020 | 5032 | 0.160 |
Why?
| | Los Angeles | 2 | 2015 | 55 | 0.150 |
Why?
| | Anthracyclines | 3 | 2023 | 42 | 0.150 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2023 | 40 | 0.150 |
Why?
| | Cancer Pain | 1 | 2018 | 20 | 0.150 |
Why?
| | Taxoids | 3 | 2023 | 93 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2019 | 182 | 0.150 |
Why?
| | Carboplatin | 1 | 2018 | 134 | 0.150 |
Why?
| | Cetuximab | 1 | 2018 | 89 | 0.150 |
Why?
| | Hyperlipidemias | 1 | 2019 | 121 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 371 | 0.150 |
Why?
| | Ireland | 2 | 2016 | 24 | 0.150 |
Why?
| | Inpatients | 2 | 2012 | 379 | 0.150 |
Why?
| | Patient Discharge | 1 | 2023 | 770 | 0.140 |
Why?
| | Financing, Government | 1 | 2017 | 40 | 0.140 |
Why?
| | Unemployment | 2 | 2009 | 39 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2018 | 1006 | 0.140 |
Why?
| | Managed Care Programs | 1 | 2018 | 132 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2015 | 99 | 0.140 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1114 | 0.140 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 49 | 0.140 |
Why?
| | Cisplatin | 1 | 2018 | 261 | 0.140 |
Why?
| | Hospital Costs | 2 | 2011 | 105 | 0.140 |
Why?
| | Public Health Practice | 1 | 2017 | 61 | 0.140 |
Why?
| | Heart Failure | 2 | 2023 | 1955 | 0.140 |
Why?
| | Patient Rights | 2 | 2019 | 10 | 0.140 |
Why?
| | Clinical Competence | 2 | 2014 | 882 | 0.140 |
Why?
| | Psychiatric Department, Hospital | 1 | 1996 | 13 | 0.140 |
Why?
| | Language | 1 | 2019 | 259 | 0.140 |
Why?
| | Child Behavior | 1 | 1998 | 217 | 0.130 |
Why?
| | Sex Distribution | 3 | 2020 | 336 | 0.130 |
Why?
| | Drug Therapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Child, Preschool | 4 | 2020 | 9093 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2019 | 412 | 0.130 |
Why?
| | Self Efficacy | 1 | 2019 | 352 | 0.130 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 48 | 0.130 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 1996 | 13 | 0.130 |
Why?
| | Smoking Cessation | 1 | 2019 | 373 | 0.130 |
Why?
| | Residence Characteristics | 2 | 2008 | 272 | 0.130 |
Why?
| | Patient Admission | 1 | 1997 | 175 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2019 | 4384 | 0.120 |
Why?
| | Infant | 3 | 2020 | 7922 | 0.120 |
Why?
| | Minority Groups | 1 | 2017 | 225 | 0.120 |
Why?
| | Child Development | 1 | 2019 | 381 | 0.120 |
Why?
| | Colorectal Surgery | 1 | 2015 | 22 | 0.120 |
Why?
| | Metformin | 1 | 2018 | 273 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 138 | 0.120 |
Why?
| | Research Design | 3 | 2007 | 916 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2019 | 322 | 0.120 |
Why?
| | Mastectomy, Segmental | 3 | 2009 | 76 | 0.120 |
Why?
| | Pilot Projects | 3 | 2021 | 1356 | 0.110 |
Why?
| | National Health Programs | 1 | 2014 | 20 | 0.110 |
Why?
| | Computer Simulation | 2 | 2023 | 858 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1996 | 175 | 0.110 |
Why?
| | Prospective Studies | 3 | 2017 | 6189 | 0.110 |
Why?
| | Systems Integration | 1 | 2013 | 37 | 0.110 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 82 | 0.110 |
Why?
| | Exercise | 2 | 2023 | 1617 | 0.110 |
Why?
| | Health Status Indicators | 1 | 2014 | 155 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2008 | 572 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 809 | 0.110 |
Why?
| | Helping Behavior | 1 | 2013 | 16 | 0.100 |
Why?
| | Child | 6 | 2020 | 18340 | 0.100 |
Why?
| | Occupations | 1 | 2012 | 35 | 0.100 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.100 |
Why?
| | Maryland | 3 | 1997 | 37 | 0.100 |
Why?
| | Mandatory Programs | 1 | 2012 | 14 | 0.100 |
Why?
| | Pregnancy, Unwanted | 1 | 2012 | 13 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2012 | 23 | 0.100 |
Why?
| | Goals | 2 | 2023 | 147 | 0.100 |
Why?
| | Cause of Death | 1 | 2014 | 360 | 0.100 |
Why?
| | Life Tables | 2 | 2008 | 17 | 0.100 |
Why?
| | Attitude to Health | 2 | 2019 | 398 | 0.100 |
Why?
| | Mental Disorders | 2 | 1997 | 884 | 0.100 |
Why?
| | Cost Control | 1 | 2012 | 38 | 0.100 |
Why?
| | Sepsis | 1 | 2017 | 505 | 0.100 |
Why?
| | Community Health Services | 1 | 2013 | 212 | 0.100 |
Why?
| | Self Disclosure | 1 | 2011 | 59 | 0.100 |
Why?
| | Contraception Behavior | 1 | 2012 | 80 | 0.100 |
Why?
| | Educational Status | 1 | 2013 | 404 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 64 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 1996 | 427 | 0.090 |
Why?
| | Retreatment | 1 | 2011 | 67 | 0.090 |
Why?
| | Mastectomy | 1 | 2011 | 99 | 0.090 |
Why?
| | Video Recording | 1 | 2011 | 141 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2010 | 2752 | 0.090 |
Why?
| | Stress, Physiological | 1 | 2013 | 375 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2014 | 489 | 0.090 |
Why?
| | Economics, Nursing | 1 | 2010 | 1 | 0.090 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.090 |
Why?
| | Access to Information | 1 | 2010 | 46 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 234 | 0.080 |
Why?
| | Consumer Behavior | 1 | 1990 | 65 | 0.080 |
Why?
| | Sex Characteristics | 2 | 2022 | 633 | 0.080 |
Why?
| | Sentinel Surveillance | 1 | 2009 | 38 | 0.080 |
Why?
| | Standard of Care | 1 | 2010 | 62 | 0.080 |
Why?
| | Occult Blood | 1 | 2009 | 24 | 0.080 |
Why?
| | Insurance Claim Reporting | 1 | 2009 | 21 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 131 | 0.080 |
Why?
| | Women's Health | 2 | 2012 | 270 | 0.080 |
Why?
| | Ohio | 1 | 2009 | 134 | 0.080 |
Why?
| | Psychometrics | 1 | 2013 | 608 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 51 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 505 | 0.080 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 59 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 767 | 0.080 |
Why?
| | Bias | 1 | 2010 | 178 | 0.080 |
Why?
| | Physical Exertion | 1 | 2010 | 200 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2013 | 570 | 0.080 |
Why?
| | Home Nursing | 1 | 2008 | 26 | 0.080 |
Why?
| | Reimbursement Mechanisms | 1 | 2009 | 76 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 315 | 0.080 |
Why?
| | Education, Professional | 1 | 2008 | 18 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2010 | 541 | 0.070 |
Why?
| | Radiotherapy | 1 | 2008 | 173 | 0.070 |
Why?
| | Pain | 2 | 2010 | 699 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 350 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 902 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 493 | 0.070 |
Why?
| | Leukemia | 1 | 2008 | 208 | 0.070 |
Why?
| | Lung Diseases | 1 | 2012 | 688 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 476 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2006 | 105 | 0.060 |
Why?
| | Charities | 1 | 2005 | 9 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2019 | 2993 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1205 | 0.060 |
Why?
| | Empirical Research | 1 | 2005 | 21 | 0.060 |
Why?
| | Hospice Care | 1 | 2007 | 184 | 0.060 |
Why?
| | Diagnosis-Related Groups | 1 | 2003 | 27 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2244 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1308 | 0.050 |
Why?
| | Pennsylvania | 1 | 2023 | 94 | 0.050 |
Why?
| | Resource Allocation | 1 | 2003 | 37 | 0.050 |
Why?
| | Florida | 2 | 2014 | 73 | 0.050 |
Why?
| | Health Surveys | 2 | 2007 | 440 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 574 | 0.050 |
Why?
| | Causality | 1 | 2023 | 105 | 0.050 |
Why?
| | Women, Working | 1 | 2002 | 9 | 0.050 |
Why?
| | Markov Chains | 2 | 2017 | 114 | 0.050 |
Why?
| | Selection Bias | 1 | 2002 | 33 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 623 | 0.050 |
Why?
| | Sampling Studies | 1 | 2002 | 90 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2001 | 2 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 721 | 0.050 |
Why?
| | Palliative Care | 1 | 2007 | 635 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 281 | 0.050 |
Why?
| | Family Characteristics | 1 | 2002 | 151 | 0.050 |
Why?
| | Normal Distribution | 1 | 2000 | 19 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2530 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2000 | 77 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2001 | 91 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 922 | 0.040 |
Why?
| | Nursing Research | 1 | 2000 | 38 | 0.040 |
Why?
| | Presenteeism | 1 | 2019 | 5 | 0.040 |
Why?
| | Etidronic Acid | 1 | 1998 | 3 | 0.040 |
Why?
| | Informed Consent | 1 | 2000 | 158 | 0.040 |
Why?
| | Alendronate | 1 | 1998 | 8 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 26 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 371 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1998 | 36 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 275 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2019 | 140 | 0.040 |
Why?
| | Ecosystem | 1 | 2022 | 495 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.040 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 116 | 0.040 |
Why?
| | Smoking Prevention | 1 | 1998 | 156 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2002 | 444 | 0.040 |
Why?
| | Spinal Fractures | 1 | 1998 | 71 | 0.040 |
Why?
| | Tennessee | 1 | 2017 | 42 | 0.040 |
Why?
| | Puberty | 1 | 1998 | 131 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 187 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 1997 | 35 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 14 | 0.030 |
Why?
| | Catheter-Related Infections | 1 | 2017 | 62 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 180 | 0.030 |
Why?
| | Schools | 1 | 2000 | 393 | 0.030 |
Why?
| | Utilization Review | 1 | 1996 | 34 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 46 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 61 | 0.030 |
Why?
| | Patient Dropouts | 1 | 1997 | 66 | 0.030 |
Why?
| | Health Policy | 1 | 2019 | 330 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 712 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2018 | 153 | 0.030 |
Why?
| | Arizona | 1 | 1996 | 67 | 0.030 |
Why?
| | Anticholesteremic Agents | 1 | 2018 | 129 | 0.030 |
Why?
| | Hospitals, Community | 1 | 1996 | 45 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 435 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1996 | 33 | 0.030 |
Why?
| | Health Resources | 2 | 2009 | 119 | 0.030 |
Why?
| | Telemedicine | 1 | 2023 | 666 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 427 | 0.030 |
Why?
| | Protoporphyrins | 1 | 1993 | 16 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 412 | 0.030 |
Why?
| | Acute Disease | 1 | 1996 | 885 | 0.030 |
Why?
| | Learning Curve | 1 | 2014 | 62 | 0.030 |
Why?
| | Lead | 1 | 1993 | 43 | 0.030 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1682 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1604 | 0.030 |
Why?
| | Societies, Medical | 1 | 2016 | 654 | 0.030 |
Why?
| | Calcium | 1 | 1998 | 1086 | 0.030 |
Why?
| | General Surgery | 1 | 2014 | 124 | 0.030 |
Why?
| | Community Participation | 1 | 2013 | 112 | 0.030 |
Why?
| | Pregnancy | 2 | 2012 | 5490 | 0.030 |
Why?
| | Stroke | 1 | 2020 | 1016 | 0.020 |
Why?
| | Risk | 1 | 2014 | 807 | 0.020 |
Why?
| | Gastroenterology | 1 | 2014 | 159 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 376 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3318 | 0.020 |
Why?
| | Contraception | 1 | 2012 | 117 | 0.020 |
Why?
| | Hepatitis B | 1 | 1991 | 51 | 0.020 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 11 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 291 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1051 | 0.020 |
Why?
| | Budgets | 1 | 2009 | 14 | 0.020 |
Why?
| | Sigmoidoscopy | 1 | 2009 | 9 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 160 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 480 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 155 | 0.020 |
Why?
| | Prostatectomy | 1 | 2009 | 97 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1991 | 254 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 444 | 0.020 |
Why?
| | Psychology | 1 | 2008 | 83 | 0.020 |
Why?
| | Demography | 1 | 2008 | 255 | 0.020 |
Why?
| | Mortality | 1 | 2008 | 282 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2006 | 69 | 0.020 |
Why?
| | Lifting | 1 | 2006 | 4 | 0.020 |
Why?
| | Illinois | 1 | 2006 | 37 | 0.020 |
Why?
| | Body Weight | 1 | 1990 | 853 | 0.020 |
Why?
| | Telephone | 1 | 2007 | 152 | 0.020 |
Why?
| | Patient Compliance | 1 | 2009 | 523 | 0.020 |
Why?
| | Prejudice | 1 | 2006 | 54 | 0.020 |
Why?
| | Burnout, Professional | 1 | 2010 | 322 | 0.020 |
Why?
| | Myocardial Revascularization | 1 | 2003 | 67 | 0.010 |
Why?
| | Vaccination | 1 | 1991 | 1198 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 384 | 0.010 |
Why?
| | Behavior | 1 | 2002 | 89 | 0.010 |
Why?
| | Episode of Care | 1 | 2001 | 5 | 0.010 |
Why?
| | Decision Trees | 1 | 2001 | 81 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 237 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 540 | 0.010 |
Why?
| | Reoperation | 1 | 2001 | 505 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 924 | 0.010 |
Why?
| | Estrogens | 1 | 1998 | 311 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1998 | 944 | 0.010 |
Why?
| | Estradiol | 1 | 1998 | 450 | 0.010 |
Why?
| | Lead Poisoning | 1 | 1993 | 17 | 0.010 |
Why?
| | ROC Curve | 1 | 1993 | 442 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 735 | 0.010 |
Why?
| | Program Evaluation | 1 | 1991 | 821 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|